For the effectiveness, animal models for AD are expected to exhibit at least the amyloid and tau pathology, and also co-pathology such as those involving α-synuclein and systemic alterations including direct dysfunction in peripheral tissues, breakdown of blood-brain-barrier (BBB) and disruption of central and peripheral homeostasis. The gene discussed is MAPT; the disease is Alzheimer disease.